Effect of preconditioning with rimazolam on inflammatory response during cardiopulmonary bypass

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200065352

Enrollment

Unknown

Registered

2022-11-03

Start date

2022-11-03

Completion date

Unknown

Last updated

2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Medicine

Interventions

Control group:physiological saline solution

Test group:Remimazolam Tosilate

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. The patients aged 18-75 years; 2. Male or non-pregnant women; 3. Cardiopulmonary bypass cardiac surgery; 4. Body mass index (BMI): 18.5-30.0 kg/m2; 5. Willing and able to sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Persistent infection and long-term use of anti-inflammatory drugs; 2. Previous cardiac surgery with cardiopulmonary bypass; 3. Complicated with aneurysm dilatation or ascending aortic dissection; 4. Patients allergic to or dependent on Remazolam; 5. Complicated with severe heart failure and renal injury; 6. Patients who participated in other clinical trials in the past 3 months.

Design outcomes

Primary

Measure	Time frame
White blood cell count;	—

Secondary

Measure	Time frame
C-reactive protein;Calcitonin;Inflammatory mediator;	—

Countries

China

Contacts

Public ContactMo Guixi

The Affiliated Hospital of Guangdong Medical University

mogxi@163.com+86 13763017403

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026